Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects

被引:25
作者
Michel, MC
Korstanje, C
Krauwinkel, W
机构
[1] Univ Amsterdam, Dept Pharmacol & Pharmacotherapy, AMC, NL-1105 AZ Amsterdam, Netherlands
[2] Yamanouchi Europe, Leiderdorp, Netherlands
关键词
tamsulosin; modified release capsule; orthostatic hypotension; benign prostatic hyperplasia; lower urinary tract symptoms; food effect;
D O I
10.1016/j.eursup.2004.11.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The effect of food on the cardiovascular safety of tamsulosin modified release (MR) capsules 0.4 mg in elderly subjects was assessed both after single and multiple dosing. Methods: Thirty-six elderly (age greater than or equal to 60 years) male volunteers were recruited and after a single-blind, placebo run-in C, period of I day were randomised to active treatment (n = 24) or placebo (n = 12). In each group the effect of food on vital signs and orthostatic stress testing was assessed in a crossover design after a single dose (Days 1 and 8 with a 7 day wash-out) and after 14 days of multiple dosing under fasting and fed conditions. Results: Changes in vital signs and orthostatic stress responses were more pronounced in the fasted than in the fed state. A total of 86 positive orthostatic stress tests were observed of which only three were symptomatic. Forty-six of these 86 tests were considered positive because of an effect on at least two criteria. The incidence of positive tests was higher in the fasted state and was increased by tamsulosin MR compared with placebo. Conclusions: Vital signs and orthostatic stress testing are more influenced by tamsulosin 0.4 mg MR capsules in the fasted than in the fed state. As tamsulosin MR is intended to be taken after breakfast or the first meal of the day, lack of compliance with this instruction may increase the incidence of cardiovascular adverse events in elderly males. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 23 条
[1]   TAMSULOSIN, A SELECTIVE ALPHA(1C)-ADRENOCEPTOR ANTAGONIST - A RANDOMIZED, CONTROLLED TRIAL IN PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION (SYMPTOMATIC BPH) [J].
ABRAMS, P ;
SCHULMAN, CC ;
VAAGE, S ;
ABEL, P ;
BAXBY, K ;
BOEMINGHAUS, F ;
DELAERE, KPJ ;
DENIS, L ;
DIJKMAN, GA ;
HASSELLUND, S ;
HOHENFELLNER, R ;
JANKNEGT, RA ;
KAPPER, BJ ;
KARTHAUS, HFM ;
KHOE, GSS ;
KIL, PJM ;
KROMANNANDERSEN, B ;
LELIEFELD, HHJ ;
LOCK, TMTW ;
MOHR, M ;
MOMMSEN, S ;
OGREID, P ;
OTTO, RW ;
PLASMAN, JWMH ;
PULL, HC ;
RYTTOV, N ;
TOLLEY, DA ;
VENEMA, PL ;
WYNDAELE, JJ ;
YPMA, AFGVM .
BRITISH JOURNAL OF UROLOGY, 1995, 76 (03) :325-336
[2]  
Andersson KE, 1997, PROSTATE, V30, P202
[3]  
Chapple CR, 1996, EUR UROL, V29, P155
[4]  
Chapple CR, 1998, BRIT J UROL, V81, P34
[5]  
CHAPPLE CR, 1995, BRIT J UROL, V76, P47
[6]   A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing [J].
de Mey, C ;
Michel, MC ;
McEwen, J ;
Moreland, T .
EUROPEAN UROLOGY, 1998, 33 (05) :481-488
[7]   Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: Impact on safety and well-being [J].
de Mey, C .
EUROPEAN UROLOGY, 1998, 34 :18-28
[8]  
de Mey Christian, 2000, Journal of Urology, V163, P220
[9]   α1-adenoceptor antagonists for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH):: State of the art [J].
Djavan, B .
EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (04) :23-30
[10]   USE OF RECOMBINANT ALPHA(1)-ADRENOCEPTORS TO CHARACTERIZE SUBTYPE SELECTIVITY OF DRUGS FOR THE TREATMENT OF PROSTATIC HYPERTROPHY [J].
FOGLAR, R ;
SHIBATA, K ;
HORIE, K ;
HIRASAWA, A ;
TSUJIMOTO, G .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 288 (02) :201-207